Ouro Medicines launched with $120 million in funding to develop antibody drugs, specifically T cell engagers, for chronic inflammatory conditions and autoimmune diseases.
Syndax Pharmaceuticals' Revuforj (revumenib) received FDA approval as the first menin inhibitor for relapsed or refractory acute leukemia with specific genetic translocations.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.